Raúl Márquez, MD’s Post

It was my honor to present our poster ((The Molecular Subtypes of Breast Cancer. A Single Institution Experience after a Decade of Syrian War)) under poster spotlight 10- Topic 2 ((Advancing Global Health Equity: Addressing Disparities in Low-Resource Settings )) in #sabcs moderated by Dr. Yara Abdou , Discussed by Dr. @Stephen Kimani. Panel 2 - Q & A by Ayla Kouli @stephen kimani, Dr Lopamudra Das Roy, MS, Ph.D, MBA , @CAROLINA PANIS,@John L. Bell, Fatima Cardoso

💬 Europe needs aging-attuned cancer palliative care, says Prof. Lieve Van den Block of the End-of-Life Care Research Group. She and Maja Furlan de Brito (University of Coimbra) addressed researchers and policymakers at today's #PalliativeCareConference2024. They presented the EU Navigate project, which supports older people with cancer in 6️⃣ European countries. ➡️eunavigate.com #MissionCancer #PalliativeCare #HorizonEU #EUCancerPlan #EUhealth

The recent Thrombosis Update paper presents an overview of public involvement as a whole and specifically reflects on how it has added value, to an international cancer associated thrombosis #CAT research. It introduces tools designed to guide teams unfamiliar with public involvement, introducing the Public Involvement in Research Impact Toolkit (PIRIT) which provides a structure for planning and reporting on public involvement activities from the study inception through conduct, to its impact. Read more here: https://lnkd.in/gjt_AmY2 Lucy Norris #ThrJournal

📢 Starting in #2025, following the completion of the pilot study we took part in 2023 with Enar Recalde Vizcay, a more integrated and transversal education framework across Europe aims to enhance cancer care Sociedad Española de Oncología Médica (SEOM) ESMO - European Society for Medical Oncology ESO Education Group

VHIO is part of #INTERACTEUROPE100, an ambitious project that brings together 100 European cancer centres committed to optimising patient care through a multidisciplinary approach. ℹ️ More info 👉 https://lnkd.in/dvmR-BmF ICERCA - Centres de Recerca de Catalunya | #CancerResearch #VHIO

"Between 1989 and 1993, inclusion of women in clinical research was NIH policy, but it was not law. In 1993, Congress wrote the NIH inclusion policy into Federal law through a section in the NIH Revitalization Act of 1993 (Public Law 103-43) titled Women and Minorities as Subjects in Clinical Research. 10  The law includes various requirements for NIH-funded research, including the following: *NIH ensures that women and minorities are included in all clinical research. *In trials including women and minorities, the trial should be designed and carried out so that it is possible to analyze whether the variables being studied affect women and minorities differently than other participants. *Cost is not an acceptable reason for excluding women and minorities. *NIH initiates programs and support for outreach efforts to recruit and retain women and minorities and their subpopulations as volunteers in clinical studies." - NIH I was already 20 when women were just starting to be considered for clinical trials...! We (Stack ) are getting there; training and upskilling the future of the clinical research workforce. https://bit.ly/4dPBY56 #womenshealth #clinicalresearch #diversity #workforcedevelopment

Cancer stigma was the focus of an NCI virtual meeting in 2022. A special issue of JNCI Monographs dedicated to global research on cancer stigma is out now, including a summary of the 2022 convening. go.nih.gov/LegTGyn NCI Center for Global Health #GlobalHealth #HealthEquity

Beautiful explanation from Arutha Kulasinghe, discussing the combined strength of multiplex IF from Akoya Biosciences, Inc. and Navinci Diagnostics PD1/PD-L1 proximity ligation assay!! Why multiplex? How can I be sure there is signalling? Where? What can this tell us about response/non-response? Could it be predictive? This assay ticks a lot of boxes ✅

🌏 TRACKER: Reflecting Australia's Diversity in Research 🔬 At TRACKER, we understand that equity begins within our team. That’s why our clinicians and researchers come from a range of cultural backgrounds, areas of expertise, and institutions, reflecting the rich diversity of the Australian community. Together, we’re not just studying lung cancer; we’re shaping solutions that truly represent the people they serve. Because when research reflects real-world diversity, it creates real-world impact. 📣 Join us in celebrating a future where everyone’s voice, perspectives and ideas matters in lung cancer research. ___ #TRACKERBiobank #DiversityInResearch #InclusiveScience #EquityInAction #LungCancerResearch

Treating the #cancer is only part of the equation and all too often cancer stigma prevents patients from seeking out additional health treatment and support to reduce the impacts of their treatment - because they and their partners assume that side effect impacts are an accepted part of life for the #cancerpatient. Women are disproportionately impacted by cancer stigma which leads to untreated - but treatable - loss of libido, discomfort, and reduced partner intimacy. Research from National Cancer Institute (NCI) sheds light on cancer stigma - and how practioners and caregivers can address it. One way - train care teams about the common, but surmountable, sexual side effects of cancer treatment and the myriad of ways to resolve them. #SexAfterCancer #SupportiveCare #CancerSupport